ADOCIA (Paris:ADOC.PA ) is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins. Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51% increase, reaching 70% in emerging countries). 15% of these patients will develop a foot ulcer during their lifetime. The markets targeted by Adocia represent more than USD 20 billion (USD 17 billion for insulin therapy and USD 3 billion for diabetic foot ulcer healing). Through its BioChaperone® state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public. Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Adocia also confirmed the value of its technology for the formulation of a fast-acting insulin analog by signing an exclusive worldwide license agreement with a major pharmaceutical company. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product.

Schneider, J. Y., Pham, V. V., Froelich, J. C. & Tsikas, D. DDAH activity is not associated with oxidative stress in elderly patients with peripheral arterial occlusive disease. Experimental gerontology 55, 159 (2014).

Obtaining approval of an NDA, or other regulatory approval, even after clinical trials that are believed to be successful, is an uncertain process.

Hi Lindy, A few words in defense of my fellow physicians: Doctors follow what is in medical textbooks. Medical textbooks don’t recognize aging as disease and have zero discussion of aging. As far as medicine is concerned, aging is natural condition; end of story. Also almost all doctors believe in human clinical trials for translation of basic science into office practice. Rapamycin is generic drug so nobody spending hundreds of millions of dollars on clinical trials. Also doctors are busy. They read journals in their specialty. They don’t read basic science stuff. So very hard for physician to discover Blagosklonny. Realize Blagosklonny is greatest scientist since Charles Darwin and then become expert on Rapamycin. Also no medical literature explaining how to use Rapamycin as anti aging drug. Also getting old and getting sick is a trillion dollar industry. What would happen if old people refused to get sick.

Total RNA was isolated from NK cells using an RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was synthesized by reverse transcription from 50 ng total RNA using a cDNA Reverse Transcriptase Kit (TaKaRa, Japan). The PCR reaction was carried out in 384-well plate using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems). Real-time PCR primers for perforin, granzyme B, and GAPDH were as follows: perforin (forward, 5′-AGCACAAGTTCGTGCCAGG-3′, and reverse, 5′-GCGTCTCTCATTAGGGAGTTTTT-3′); granzyme B (forward, 5′-CCACTCTCGACCCTACATGG-3′, and reverse, 5′-GGCCCCCAAAGTGACATTTATT-3′); GAPDH (forward, 5′-CATGGCCTTCCGTGTTCCTA-3′, and reverse, 5′-ATGCCTGCTTCACCACCTTCT-3′).

If applicable, the penny stock rules may make it difficult for investors to sell their ordinary shares. Because of the rules and restrictions applicable to a penny stock, there is less trading in penny stocks and the market price of our ordinary shares may be adversely affected. Also, many brokers choose not to participate in penny stock transactions. Accordingly, investors may not always be able to resell their ordinary shares publicly at times and prices that they feel are appropriate and the market price of our ordinary shares may be adversely affected.

Aramchol may produce undesirable side effects or have other properties that could delay or prevent its regulatory approval or result in significant negative consequences following marketing approval, if any, which could substantially increase commercialization costs or even force us to cease operations.

        From time to time, we may also publish interim, "top-line" or preliminary data from our clinical studies. For example, in December 2018, we announced positive top-line results from our Phase 2 clinical trial evaluating zilucoplan for the treatment of gMG. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line data remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or interim data we previously published. As a result, these data should be viewed with caution until the final data are available. Adverse changes between preliminary or interim data and final data could significantly harm our business prospects.

Aramchol is a synthetic conjugate of cholic acid, or a type of bile acid, and arachidic acid, or a type of saturated fatty acid, both of which, in their non-synthetic forms, are naturally occurring. The conjugated molecule acts upon important metabolic pathways, reducing fat accumulation in the liver, improving fatty acid oxidation and regulating the transport of cholesterol. The ability of Aramchol to decrease liver fat content may also reduce the inflammation and fibrosis in the liver and the risk of cardiovascular complications associated with NASH. Pre-clinical studies suggest Aramchol effect on fibrosis is also direct via collagen production from human hepatic stellate cells. We believe that Aramchol’s ability to reduce liver fat and liver fibrosis and the safety profile observed to date will enable it to be a safe and effective treatment for all stages of NASH in patients who are overweight or obese and have pre diabetes or type II diabetes mellitus and prevent the hepatic complications associated therewith.

Yeagle, P. L. The biophysics and cell biology of cholesterol: An hypothesis for the essential role of cholesterol in mammalian cells. in Cholesterol in Membrane Models (ed. Finegold, L. ) 1–10 (CRC Press, Boca Raton, 1993).

Dubey, A. K., Basu, B. & Bandyopadhyay, A. Pulsed electrical stimulation and surface charge induced cell growth on multistage spark plasma sintered hydroxyapatite-barium titanate piezobiocomposite. J. Am. Chem. Soc. 97, 481–489 (2014).

Sysa-Shah, P. et al. Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. PLoS ONE 7, e42805, 10.1371/journal.pone.0042805 (2012).